Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2019

Open Access 01-12-2019 | Arterial Occlusive Disease | Research article

The effect of mild agonist stimulation on the platelet reactivity in patients with type 2 diabetes mellitus

Authors: Razie Mahmoodian, Morteza Salimian, Mohsen Hamidpour, Ali Akbar Khadem-Maboudi, Ahmad Gharehbaghian

Published in: BMC Endocrine Disorders | Issue 1/2019

Login to get access

Abstract

Background

Patients with type 2 diabetes mellitus (T2DM) have accelerated atherosclerosis as a pro thrombotic state that is associated with the platelet activation priming. Platelets, which undergo the continuous mild stimulation, may lose their sensitivity to react to a strong stimulation. The present study aimed to investigate activation responses of platelets to mild and subsequent strong stimulations in patients with T2DM and healthy individuals.

Methods

Blood samples, which were taken from 40 patients with T2DM and 35 healthy individuals, were collected into the citrate containing tubes. The samples were subjected to the soft centrifugation to prepare the platelet rich plasma (PRP). Platelets in PRP samples were treated at a low (1 μM) concentration and then at a high (10 μM) concentration of ADP. Before and after stimulation with different doses of ADP, levels of CD62P expression and formation of platelet micro particles (PMPs) were measured using a flow cytometry method.

Results

The platelets from patients with T2DM had higher levels of CD62P expression before any stimulation (P = 0.003) than control samples. Platelets, which underwent the mild stimulation, indicated lower responses to CD62P expression, but higher PMPs formation after stimulation with high dose of ADP. Patients with T2DM had higher platelet micro particles in all states with the ADP stimulation. (P = 0.004, SD: ±74.52).

Conclusions

The flow cytometry data indicated that platelets were pre-active and associated with metabolic conditions in patients with type 2 diabetes mellitus. The induction of desensitization state helped platelets to reduce the platelet activation and sensitivity to ADP in a diabetic environment. Furthermore, the production of platelets micro-particles was high in the patients; and desensitized platelets were more susceptible to shedding of micro-particles.
Literature
1.
go back to reference Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36:s67–74.CrossRef Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36:s67–74.CrossRef
2.
go back to reference Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes. 2000;49:975–80.CrossRef Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes. 2000;49:975–80.CrossRef
3.
go back to reference Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res. 2010;7(4):251–9.CrossRef Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res. 2010;7(4):251–9.CrossRef
4.
go back to reference Schneider DJ. Actors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.CrossRef Schneider DJ. Actors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.CrossRef
5.
go back to reference Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JCM, Hoekstra JBL. Hyperglycaemia, a prothrombotic factor? Journal Thrombosis and Haemostasis. 2010;8:1663–9.CrossRef Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JCM, Hoekstra JBL. Hyperglycaemia, a prothrombotic factor? Journal Thrombosis and Haemostasis. 2010;8:1663–9.CrossRef
6.
go back to reference Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108(12):1527–32.CrossRef Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108(12):1527–32.CrossRef
7.
go back to reference Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307–12.CrossRef Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307–12.CrossRef
8.
go back to reference SHANTSILA E, KAMPHUISEN PW, LIP GYH. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost. 2010;8:2358–68.CrossRef SHANTSILA E, KAMPHUISEN PW, LIP GYH. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost. 2010;8:2358–68.CrossRef
9.
go back to reference Ferreiro JL, Angiolillo DJ. Diabetes and anti-platelet therapy in acute coronary syndrome. Circulation. 2011;123:798–813.CrossRef Ferreiro JL, Angiolillo DJ. Diabetes and anti-platelet therapy in acute coronary syndrome. Circulation. 2011;123:798–813.CrossRef
10.
go back to reference Morel O, Jesel L, Freyssinet J-M, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arteriosclerosis Thrombosis and Vascular Biology. 2011;31:15–26.CrossRef Morel O, Jesel L, Freyssinet J-M, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arteriosclerosis Thrombosis and Vascular Biology. 2011;31:15–26.CrossRef
11.
go back to reference Van der Pol E, Böing AN, Gool EL, Nieuwland R. Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost. 2016;14:48–56.CrossRef Van der Pol E, Böing AN, Gool EL, Nieuwland R. Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost. 2016;14:48–56.CrossRef
12.
go back to reference Buzas I, György B, Nagy G, Falus A, Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol. 2014;10:356–64.CrossRef Buzas I, György B, Nagy G, Falus A, Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol. 2014;10:356–64.CrossRef
13.
go back to reference Van der Pol E, Harrison P. From platelet dust to gold dust: physiological importance and detection of platelet microvesicles. platelets. 2017;28(3):211–3.CrossRef Van der Pol E, Harrison P. From platelet dust to gold dust: physiological importance and detection of platelet microvesicles. platelets. 2017;28(3):211–3.CrossRef
14.
go back to reference Morel O, Jesel L, Abbas M, Morel N. Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost. 2013;39:477–88.CrossRef Morel O, Jesel L, Abbas M, Morel N. Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost. 2013;39:477–88.CrossRef
15.
go back to reference Baurand A, Eckly A, Bari N, Léon C, Hechler B, Cazenave J-P, Gachet C. Desensitization of the platelet aggregation response to ADP: differential Down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost. 2000;84:489–91.CrossRef Baurand A, Eckly A, Bari N, Léon C, Hechler B, Cazenave J-P, Gachet C. Desensitization of the platelet aggregation response to ADP: differential Down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost. 2000;84:489–91.CrossRef
16.
go back to reference Siljander PR-M. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. blood. 2003;103:1333–41.CrossRef Siljander PR-M. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. blood. 2003;103:1333–41.CrossRef
17.
go back to reference Bünemann M, Lee KB, Pals-Rylaarsdam R, Roseberry AG, Hosey MM. Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol. 1999;61:169–92.CrossRef Bünemann M, Lee KB, Pals-Rylaarsdam R, Roseberry AG, Hosey MM. Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol. 1999;61:169–92.CrossRef
18.
go back to reference Holme S, Holmsen H. ADP-induced refractory state of platelets in vitro (I – methodological studies on aggregation in platelet rich plasma). Eur J Haematol. 1975;15:96–103. Holme S, Holmsen H. ADP-induced refractory state of platelets in vitro (I – methodological studies on aggregation in platelet rich plasma). Eur J Haematol. 1975;15:96–103.
19.
go back to reference Lunkes GI, Lunkes D, Stefanello F, Morsch A, Morsch VM, Mazzanti CM, Schetinger MRC. Enzymes that hydrolyze adenine nucleotides in diabetes and associated pathologies. Thromb Res. 2003;(4):194.CrossRef Lunkes GI, Lunkes D, Stefanello F, Morsch A, Morsch VM, Mazzanti CM, Schetinger MRC. Enzymes that hydrolyze adenine nucleotides in diabetes and associated pathologies. Thromb Res. 2003;(4):194.CrossRef
20.
go back to reference MUNDELL SJ, BARTON JF, MAYO-MARTIN MB, HARDY AR, POOLE AW. Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemost. 2008;6:1393–404.CrossRef MUNDELL SJ, BARTON JF, MAYO-MARTIN MB, HARDY AR, POOLE AW. Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemost. 2008;6:1393–404.CrossRef
21.
go back to reference Hardy AR, PBC JL, Benovic JL, Poole AW, Mundell SJ. P2Y1 and P2Y12 receptors forADP desensitize by distinct kinase-dependent mechanisms. blood. 2005;105:3552–60.CrossRef Hardy AR, PBC JL, Benovic JL, Poole AW, Mundell SJ. P2Y1 and P2Y12 receptors forADP desensitize by distinct kinase-dependent mechanisms. blood. 2005;105:3552–60.CrossRef
22.
go back to reference Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476–85.CrossRef Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476–85.CrossRef
23.
go back to reference Ni H. The platelet “sugar high” in diabetes. blood. 2012;119:5949–51.CrossRef Ni H. The platelet “sugar high” in diabetes. blood. 2012;119:5949–51.CrossRef
24.
go back to reference Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282–91.CrossRef Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282–91.CrossRef
26.
go back to reference Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clinical & Experimental Immunology. 2000;121:437–43.CrossRef Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clinical & Experimental Immunology. 2000;121:437–43.CrossRef
27.
go back to reference Yungen M. Platelet function in diabetes mellitus relationships to hyperglycaemia, antidiabetic treatment and microangiopathy: Karolinska University Press; 2005. p. 91–7140-062-1. Yungen M. Platelet function in diabetes mellitus relationships to hyperglycaemia, antidiabetic treatment and microangiopathy: Karolinska University Press; 2005. p. 91–7140-062-1.
28.
go back to reference Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with DiabetesMellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;14:719–42. Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with DiabetesMellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;14:719–42.
29.
go back to reference Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: targets and tools in cardiovascular disease. Cell PRESS. 2011;32:659–65. Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: targets and tools in cardiovascular disease. Cell PRESS. 2011;32:659–65.
30.
go back to reference Tan KT, Lip GYH. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost. 2005;94:488–92.CrossRef Tan KT, Lip GYH. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost. 2005;94:488–92.CrossRef
31.
go back to reference Vajen T, et al. Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype. Journal of Extracellular Vesicles. 2017;6.CrossRef Vajen T, et al. Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype. Journal of Extracellular Vesicles. 2017;6.CrossRef
32.
go back to reference Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries FA. Evidence for abnormal glycoprotein receptor expression on diabetes mellitus. Eur J Clin Invest. 1990;20:166–70. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries FA. Evidence for abnormal glycoprotein receptor expression on diabetes mellitus. Eur J Clin Invest. 1990;20:166–70.
33.
go back to reference Alexandru N, Badila E, Weiss E, Cochior D, Stępień E, Georgescu A. Vascular complications in diabetes: microparticles and microparticle associated microRNAs as active players. Biochem Biophys Res Commun. 2016;472(1):1–10.CrossRef Alexandru N, Badila E, Weiss E, Cochior D, Stępień E, Georgescu A. Vascular complications in diabetes: microparticles and microparticle associated microRNAs as active players. Biochem Biophys Res Commun. 2016;472(1):1–10.CrossRef
34.
go back to reference Nomura S. Microparticle and Atherothrombotic diseases. Journal of Atherisclerosis and thrombosis, vol. 23; 2016. p. 1. Nomura S. Microparticle and Atherothrombotic diseases. Journal of Atherisclerosis and thrombosis, vol. 23; 2016. p. 1.
35.
go back to reference Imene Melki NT, Zufferey A, Boilard E. Platelet microvesicles in health and disease. platelets. 2017;4:710–953. Imene Melki NT, Zufferey A, Boilard E. Platelet microvesicles in health and disease. platelets. 2017;4:710–953.
36.
go back to reference Pierce GF. Inflammation in nonhealing diabetic wounds. Am J Pathol. 2001;159(2):403.CrossRef Pierce GF. Inflammation in nonhealing diabetic wounds. Am J Pathol. 2001;159(2):403.CrossRef
37.
go back to reference Icli B, Nabzdyk CS, Lujan-Hernandez J, Cahill M, Auster ME, Wara AKM, Sun X, Ozdemir D, Giatsidis G, Orgill DP, Feinberg MW. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. J Mol Cell Cardiol. 2016;9:91–151. Icli B, Nabzdyk CS, Lujan-Hernandez J, Cahill M, Auster ME, Wara AKM, Sun X, Ozdemir D, Giatsidis G, Orgill DP, Feinberg MW. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. J Mol Cell Cardiol. 2016;9:91–151.
Metadata
Title
The effect of mild agonist stimulation on the platelet reactivity in patients with type 2 diabetes mellitus
Authors
Razie Mahmoodian
Morteza Salimian
Mohsen Hamidpour
Ali Akbar Khadem-Maboudi
Ahmad Gharehbaghian
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2019
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-019-0391-2

Other articles of this Issue 1/2019

BMC Endocrine Disorders 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.